Prestige Consumer (NYSE: PBH) grants director 2,981 RSUs valued at $155,000
Rhea-AI Filing Summary
DArecca James reported acquisition or exercise transactions in this Form 4 filing.
Prestige Consumer Healthcare Inc. director James DArecca received a grant of 2,981 restricted stock units, valued at $155,000 based on a $52.00 share price, under the director compensation program. The units vest after one year and will be settled in common stock upon specified separation, death, or change-in-control events, bringing his reported holdings to 9,572 shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 2,981 shares
Net Buy
1 txn
Insider
DArecca James
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock, par value $0.01 per share F1 | 2,981 | $0.00 | $0.00 |
Holdings After Transaction:
Common Stock, par value $0.01 per share — 9,572 shares (Direct)
Footnotes (1)
- F1. The Reporting Person received 2,981 restricted stock units equal to $155,000 divided by the closing stock price of $52.00 on August 4, 2026, in connection with the Issuer's director compensation program. The restricted stock units vest on the first anniversary of grant and will be settled by delivery to the Reporting Person of one share of common stock of the issuer for each vested restricted stock unit promptly following the earliest of (1) the Reporting Person's death, (ii) the Reporting Person's separation or (iii) change in control.
Key Figures
Restricted stock units granted: 2,981 shares
Grant value: $155,000
Reference share price: $52.00
+1 more
4 metrics
Restricted stock units granted
2,981 shares
Equity award to director James DArecca on August 4, 2026
Grant value
$155,000
Equity value divided by closing stock price to determine RSUs
Reference share price
$52.00
Closing stock price on August 4, 2026 used to compute RSUs
Shares following transaction
9,572 shares
Total reported holdings after the grant to James DArecca
Key Terms
restricted stock units, director compensation program, change in control
3 terms
restricted stock units financial
"The Reporting Person received 2,981 restricted stock units equal to $155,000"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
director compensation program financial
"in connection with the Issuer's director compensation program"
change in control regulatory
"promptly following the earliest of (1) the Reporting Person's death, (ii) the Reporting Person's separation or (iii) change in control."
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What equity award did PBH director James DArecca receive?
Director James DArecca received 2,981 restricted stock units under Prestige Consumer Healthcare’s director compensation program. The grant is valued at $155,000, determined by dividing that amount by the company’s $52.00 closing stock price on August 4, 2026.
How was the number of restricted stock units for PBH calculated?
The award of 2,981 restricted stock units was calculated by dividing a grant value of $155,000 by Prestige Consumer Healthcare’s closing stock price of $52.00 on August 4, 2026, as part of the issuer’s director compensation program.
When do the PBH restricted stock units granted to James DArecca vest?
The 2,981 restricted stock units granted to director James DArecca vest on the first anniversary of the August 4, 2026 grant date. Vesting reflects completion of the required service period under Prestige Consumer Healthcare’s director compensation program.
Was the PBH equity award to James DArecca a market purchase?
No. The filing describes the transaction as a grant or award acquisition of 2,981 restricted stock units with a per-share transaction price of $0.00, provided as part of Prestige Consumer Healthcare’s director compensation program rather than a market purchase.